Skip to main content
SpringerLink
Log in

Aclidinium/formoterol for COPD cost saving in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by AstraZeneca Spain.

Reference

  • Capel M, et al. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clinical Drug Investigation : 13 Apr 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0646-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aclidinium/formoterol for COPD cost saving in Spain. PharmacoEcon Outcomes News 803, 2 (2018). https://doi.org/10.1007/s40274-018-4929-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4929-8

Search

Navigation